Bristol-Myers Squibb: Compelling Value From The New Products Portfolio And 4.5% Yield

Solskin Bristol-Myers Squibb Company (NYSE:BMY) has built momentum off its Q4 earnings report which shares up more than 11% in the past month. Compared to a difficult 2023 where the stock lost nearly a third of its value, the recent price action suggests bulls are back alongside an improving fundamental outlook. The story with BMY has been an ongoing shift in its drug portfolio between weaker sales from its legacy brands, balanced by stronger trends from new product launches. Favorably, the outlook is for a ...